share_log

Nemaura Medical Analyst Ratings

Benzinga Analyst Ratings ·  Aug 19, 2022 07:11
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
08/19/2022 268.66% HC Wainwright & Co. $12 → $8 Maintains Buy
03/29/2022 453% HC Wainwright & Co. → $12 Initiates Coverage On → Buy
12/02/2021 245.62% EF Hutton → $7.5 Initiates Coverage On → Buy

Nemaura Medical Questions & Answers

What is the target price for Nemaura Medical (NMRD)?

The latest price target for Nemaura Medical (NASDAQ: NMRD) was reported by HC Wainwright & Co. on August 19, 2022. The analyst firm set a price target for $8.00 expecting NMRD to rise to within 12 months (a possible 268.66% upside). 3 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for Nemaura Medical (NMRD)?

The latest analyst rating for Nemaura Medical (NASDAQ: NMRD) was provided by HC Wainwright & Co., and Nemaura Medical maintained their buy rating.

When is the next analyst rating going to be posted or updated for Nemaura Medical (NMRD)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Nemaura Medical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Nemaura Medical was filed on August 19, 2022 so you should expect the next rating to be made available sometime around August 19, 2023.

Is the Analyst Rating Nemaura Medical (NMRD) correct?

While ratings are subjective and will change, the latest Nemaura Medical (NMRD) rating was a maintained with a price target of $12.00 to $8.00. The current price Nemaura Medical (NMRD) is trading at is $2.17, which is out of the analyst's predicted range.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment